Show simple item record

dc.contributor.authorMcIntosh, Bryan
dc.contributor.authorFascia, M.
dc.date.accessioned2014-11-12T16:56:28Z
dc.date.available2014-11-12T16:56:28Z
dc.date.issued2014
dc.identifier.citationMcIntosh B and Fascia M (2014) The Highest Mountain – T- Cell Technology. British Journal of Healthcare Management. 20(6): 281–285.en_US
dc.identifier.urihttp://hdl.handle.net/10454/6600
dc.description.abstractT-lymphocytes (T-cell) therapy offers a treatment for cancers. Developing this technology in the future provides the opportunity to revolutionise treatment and to make cancer a chronic condition. T-cells in themselves are a type of lymphocytes (itself a type of white blood cell) that play a central role in cell mediated immunity. They can be distinguished from other lymphocytes, such as B-cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. T-cells have the capacity to destroy diseased cells, but tumours present a considerable challenge that reduces their impact. As cancer cells are frequently ‘invisible’ to the immune system, and they create an environment that suppresses T-cell activity., genetic engineering of T-cells can be used therapeutically to overcome these challenges. T-cells can be taken from the blood of cancer patients and then modified to recognise and destroy cancer-specific antigens.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://www.magonlinelibrary.com/doi/abs/10.12968/bjhc.2014.20.6.281en_US
dc.subjectCancer; Leukaemia; T-cells; Immunosuppression; T-cell receptor; TCRen_US
dc.titleThe Highest Mountain – T- Cell Technologyen_US
dc.status.refereedyesen_US
dc.typeArticleen_US
dc.type.versionAccepted Manuscripten_US
refterms.dateFOA2018-07-19T13:53:03Z


Item file(s)

Thumbnail
Name:
BJHCM The Highest Mountain T- ...
Size:
314.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record